MIRA
INFORM REPORT
|
Report Date : |
11.10.2008 |
IDENTIFICATION
DETAILS
|
Name : |
MARYLAND PHARMA INC. |
|
|
|
|
Registered Office : |
9345 Maxwell Court, Laurel, MD
20723 |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
30.10.2007 |
|
|
|
|
Legal Form : |
Corporation for Profit |
|
|
|
|
Line of Business : |
Wholesaler of
Pharmaceuticals |
RATING &
COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
Maximum Credit Limit : |
USD 5,000 |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
REQUIRED CREDIT |
ADVISED CREDIT |
|
MAXIMUM |
5,000 USD |
GEOPOLITICS
|
POLITICAL DATA |
ECONOMIC DATA |
||
|
FORM OF GOVERNMENT ECONOMIC RISK |
Federal
|
CURRENCY BRANCH SITUATION |
USD Satisfying |
IDENTIFICATION
|
Company Name: |
Maryland
Pharma Inc. |
||
|
Address: |
9345 Maxwell
Court, Laurel, MD 20723, USA |
||
|
Phone: Facsimile: ID: State: Managers: |
+ 1 (301) 776-3354 NA D12204848 Maryland Gunvantrai K Changela, Director |
Date founded: |
Oct 30,
2007
Corporation for Profit N.A. N.A. 2
employees |
|
Legal form: |
|||
|
Stock: Value: |
|||
|
Staff: |
|||
|
Business: |
Wholesales pharmaceuticals |
||
BANKS
Bank of America
BUSINESS
Business & Operations:
Maryland Pharma, Inc. is a company, located in Laurel, Maryland.
Maryland Pharma, Inc's line of business is wholesaler drugs and sundries.
We called the company to have further information about the exact
activity.
As of today, they have not called back.
Industry Overview:
About 1,500
companies in the US manufacture and market medicinal drugs, with combined
annual US revenue over $200 billion. Large US manufacturers include Merck,
Pfizer, Bristol-Myers Squibb, Abbott, and Eli Lilly. The industry is highly
concentrated: the 50 largest companies control more than 80 percent of the
market.
The traditional
drug manufacturing industry increasingly overlaps with the biotechnology
industry, which is a source of many new medical treatments. To a large extent,
traditional drug manufacturers are becoming development and marketing companies
that acquire new drugs from smaller research companies.
The industry is marked by rapid advances in scientific knowledge that
produce ever-more effective medicines. Profitability is determined mainly by
the ability to discover new drugs. The industry is dominated by the large
manufacturers/marketers that manufacture drugs, have large research operations,
and also have large clinical testing, marketing, and distribution capabilities.
Small companies are mainly research operations or manufacturers of
non-prescription products. Because of the high value of the product, average
revenue per employee is a very high $600,000.
SHAREHOLDERS – SUBSIDIARIES
– MANAGERS
The director of the company
is:
Gunvantrai K Changela,
Director.
He is among the main
shareholders.
FINANCIALS – COMMERCIAL TRENDS
AND FORECAST
As a private company,
Maryland Pharma Inc. does not publish any financials.
However our source provide us with the following information :
|
Fiscal Year USD |
12/31/2007 |
|
||
|
Turnover
|
210,000 |
||
LEGALS
0 Suits
0 Judgments
0 Liens
0 Collection Claims
Reported
0 NSF Cheques Reported
0 UCC Filings
RATING
Local credit bureau gave a
correct credit rate.
The Company is in “good
standing”.
This means only that all
local and federal taxes were paid on due date.
Payments are made on a
regular basis.
The cash is correct.
Our final opinion:
This is a new small-size
business worldwide.
A credit line may be
considered.
A business connection may
be conducted.
SUMMARY
|
FINANCIAL SUMMARY |
DEBT COLLECTIONS
AND PAYMENTS |
||
|
PROFITABILITY INDEBTNESS CASH |
Correct Controlled Correct |
PUBLIC PAYMENTS |
No Regular |
ADVISED
CREDIT
5,000 USD
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.48.72 |
|
UK Pound |
1 |
Rs.82.17 |
|
Euro |
1 |
Rs.65.90 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)